Bavituximab
- Generic Name
- Bavituximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 648904-28-3
- Unique Ingredient Identifier
- Q16CT95N25
- Background
Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.
- Indication
Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT05249569
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 7
- Registration Number
- NCT04150900
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- OncXerna Theraputics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04099641
- Locations
- 🇺🇸
UC Health Office of Clinical Research, Cincinnati, Ohio, United States
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
🇺🇸Sara Cannon Research Institute, Nashville, Tennessee, United States
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- David Hsieh
- Target Recruit Count
- 35
- Registration Number
- NCT03519997
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT03139916
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01634685
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01323062
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States
Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection
- Conditions
- Interventions
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT01273948
- Locations
- 🇬🇪
LTD Vakhtang Bochorishvili Anticeptic Centre, Tbilisi, Georgia
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT01160601
- Locations
- 🇬🇪
Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇷🇺State Institution of Healthcare " Ivanovo Regional Oncology Dispensary ", Ivanovo, Russian Federation
🇮🇳Kodlikeri Memorial Hospital, Aurangabad, Maharashtra, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.